[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Texas Southwestern Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":683},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,182,0,25,[9,46,72,96,136,161,190,213,240,280,302,327,351,383,411,440,473,500,534,554,576,606,624,644,664],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100652727","aging-and-exercise-impacts-on-glymphatic-function-100652727",false,"NCT07775196","Aging and Exercise Impacts on Glymphatic Function","Impact of Aging and Exercise on Glymphatic Function Using Multi-modal MRI","Inclusion Criteria:\n\n* age 25-75 years old\n* cognitively unimpaired (CU)\n* Mini-Mental State Examination (MMSE) score ≥27 at enrollment screening\n* matched gender\n* all racial\u002Fethnic groups\n\nExclusion Criteria:\n\n* pregnant women\n* history of stroke or other major cerebrovascular disease;\n* diagnosis of Alzheimer's disease (AD) or other types of dementia;\n* diagnosis of major neurologic and psychiatric disorders (e.g., Parkingson's disease, major depression);\n* history of prior head trauma, significant autoimmune disorders,\n* sleep apnea;\n* major systemic illness likely to affect the central nervous system, e.g., uncontrolled diabetes, severe cardiovascular disease, cancer, etc.;\n* prior or current alcoholism or drug abuse;\n* resistant hypertension (SBP ≥140 or DBP ≥ 90 mmHg despite 3 antihypertensive drugs at maximal doses);\n* orthostatic hypotension defined as the third standing systolic blood pressure (SBP) \\\u003C 100mmHg; any contraindications to having a MRI, e.g., claustrophobia, pacemaker or other medical device of metal;\n* any conditions judged by the investigators to be medically inappropriate, risky or likely to cause poor study compliance.",true,"ALL","25 Years","75 Years",{"count":22,"type":23},240,"ESTIMATED","INTERVENTIONAL",[26],"NA","This is a prospective, interventional, non-blinded, single center research project that will recruit cognitively unimpaired subjects in the 25-55 year old and 55-75 year old range. This study will use acute aerobic exercise as a natural intervention model to increase cardiac activity which may further drive the glymphatic function. There will be no randomization, and all enrolled subjects will participate in the exercise session.\n\nHypotheses: revealed by the multi-modal magnetic resonance imaging (MRI) approach, glymphatic dysfunction increases with age and is associated with preclinical Alzheimer's Disease (AD) pathology in cognitively unimpaired individuals. Using acute aerobic exercise as a human model, the enhancement of cerebrospinal fluid-interstitial fluid (CSF-ISF) exchange caused by elevated cardiac activity and paravascular cerebrospinal fluid (pCSF) dynamics can be validated.",[14],[30,31,32,33],"Aging","Exercise","Glymphatic Function","Alzheimer's Disease","NOT_YET_RECRUITING","2026-08-17",{"date":37,"type":38},"2026-08-20","ACTUAL",{"date":40,"type":23},"2026-12",{"date":42,"type":23},"2029-12",{"name":44,"class":45},"University of Texas Southwestern Medical Center","OTHER",{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":24,"phases":56,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100450463","phase-1-phase-12a-study-of-belantamab-mafodotin-in-relapsed-or-refractory-al-amyloidosis-100450463","NCT05145816","Phase 1\u002F2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis","A Dose-Finding and Proof-of-Concept Phase 1\u002F2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis","Inclusion Criteria:\n\n1. Participants medically diagnosed with relapsed or refractory Amyloid Light Chain Amyloidosis (AL amyloidosis) with one or more line of treatment as below:\n\n   1. Must have received a proteosome inhibitor, alkylator and anti-cluster of differentiation 38 (CD38) antibody (e.g., daratumumab - for patients who were eligible to receive in newly diagnosed AL Amyloidosis) and autologous stem cell transplant (for transplant eligible candidates).\n\n      OR\n   2. Failed treatment and\u002For intolerant\u002Fineligible for above agents\n\n   NOTE: Patients who fail to achieve Partial Hematological Response or better after 2 cycles of induction therapy for newly diagnosed AL Amyloidosis are also eligible.\n2. Participant must be over 18 years of age inclusive, at the time of signing the informed consent.\n3. Participant and Disease Characteristics: Patient must have primary systemic AL amyloidosis, histologically confirmed at the initial diagnosis before initiation of 1st-line treatment by positive Congo red stain with green birefringence on polarized light microscopy, Or characteristic appearance by electron microscopy AND confirmatory AL amyloid typing (mass spectrometry-based proteomic analysis or immunofluorescence).\n4. Patient must have measurable disease within 28 days prior to registration; serum quantitative immunoglobulins (immunoglobulin G (IgG), immunoglobulin A (IgA), and immunoglobulin M (IgM), serum free kappa and lambda, and serum protein electrophoresis (SPEP) with M-protein quantification must be obtained within 14 days prior to registration.\n5. Measurable disease of amyloid light chain amyloidosis as defined by at least One of the following:\n\n   a. Serum M-protein ≥0.5 g\u002FdL by protein electrophoresis (routine serum protein electrophoresis and immunofixation).\n\n   b. Serum free light chain ≥50 mg\u002FL with an abnormal kappa: lambda ratio or the difference between the involved and uninvolved free light chains (dFLC) ≥50 mg\u002FL.\n6. One or more organs impacted by AL Amyloidosis according to consensus guidelines below per National Comprehensive Cancer Network (NCCN)Guidelines Version 1.2016:\n\n   a. Cardiac Involvement i. Mean left ventricular wall thickness on echocardiogram greater than or equal to 12 mm in the absence of hypertension or valvular heart disease, OR N-terminal fragment brain natriuretic protein (NT-pro) brain natriuretic peptide (BNP) greater than 332 ng\u002FmL provided that patient does not have impaired renal function (as defined by calculated creatinine clearance less than 25 mL\u002Fmin) within 14 days prior to registration, OR prior cardiac biopsy (at time of diagnosis) showing amyloid deposition with past documented or presently noted clinical symptoms and signs supportive of a diagnosis of heart failure in the absence of an alternative explanation for heart failure.\n\n   b. Non-Cardiac Organ Involvement\n\n   i. Kidney: albuminuria greater than or equal to 500 mg per day on a 24-hour urine specimen within 35 days prior to registration, OR prior kidney biopsy (at the time of diagnosis) showing amyloid deposition.\n\n   ii. Liver: hepatomegaly (total liver span \\> 15 cm) as demonstrated by computed tomography (CT) or magnetic resonance imaging (MRI) within 35 days prior to registration OR alkaline phosphatase (ALP) greater than 1.5 times the institutional upper limit of normal within 14 days prior to registration, OR prior liver biopsy (at the time of diagnosis) showing amyloid deposition.\n\n   iii. Gastrointestinal tract: direct biopsy verification with symptoms.\n\n   iv. Lung: biopsy verifications with symptoms and interstitial radiographic pattern.\n\n   v. Soft tissue: tongue enlargement, clinical, arthropathy, claudication, presumed vascular amyloid, skin involvement, carpal tunnel syndrome, myopathy by biopsy or pseudohypertrophy.\n7. Patients must have completed other systemic therapy or investigational drug ≥ 28 days or five half-lives prior to registration, surgery (other than biopsies) ≥ 28 days prior to registration, and any autologous stem cell transplant (ASCT) ≥ 100 days prior to registration.\n8. Patients must have a complete medical history and physical exam within 14 days prior to registration.\n9. New York Heart Association (NYHA) Class 1 - 3a which has been clinically stable for 56 days before registration\n10. Eastern Cooperative Oncology Group (ECOG) performance score 0, 1 or 2\n11. Left ventricular ejection fraction (LVEF) by echocardiogram (ECHO) \\> 35% within 28 days prior to registration.\n12. Adequate organ system functions within 14 days of registration as defined by the laboratory assessments below:\n\n    a) Hematologic i) Absolute neutrophil count (ANC): ≥1.0 × 10(9)\u002F L \\* ii) Hemoglobin: ≥8.0 g\u002FdL \\* iii) Platelets: ≥50 × 10(9)\u002FL \\*\n\n    b) Hepatic i) Total bilirubin: ≤1.5 × upper limit of normal (ULN); (Isolated bilirubin ≥1.5 × ULN is acceptable if bilirubin is fractionated, and direct bilirubin is \\\u003C35%) ii) Alanine aminotransferase (ALT): ≤2.5 × ULN\n\n    c) Renal i) Estimated glomerular rate (eGFRª): ≥30 mL\u002Fmin\u002F1.73 m2 Note: Laboratory results obtained during Screening should be used to determine eligibility criteria. In situations where laboratory results are outside the permitted range, the investigator may re-test the participant and the subsequent within range screening result may be used to confirm eligibility.\n\n    \\* Without growth factor or cell transfusion support for the past 14 days prior to testing, excluding erythropoietin.\n\n    ª As calculated by Modified Diet in Renal Disease (MDRD) formula (Appendix 4 in Protocol)\n13. Females of childbearing potential: These participants must have a negative baseline pregnancy test using serum or urine within 14 days prior to starting therapy and a confirmatory negative serum pregnancy test with a sensitivity of at least 50 mIU\u002FmL within 72 hours prior to registration; females of childbearing potential must also agree:\n\n(1) to have a pregnancy test prior to the start of each treatment cycle and (2) to either commit to continued abstinence from heterosexual intercourse or to use effective contraception while receiving study drug and for at least 4 months after receiving the last dose of study drug; females are considered to be of childbearing potential if they have had menses at any time in the preceding 24 consecutive months; in addition to routine contraceptive methods, effective contraception also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, she is responsible for beginning contraceptive measures.\n\n1. Is a woman of child bearing potential (WOCBP) and using a contraceptive method that is highly effective (with a failure rate of \\\u003C1% per year), preferably with low user dependency (as described in Appendix 9), during the intervention period and for at least 4 months after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.\n2. A WOCBP must have a negative serum pregnancy test (as required by local regulations) within 72 hours before the first dose of study intervention.\n3. The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with a nearly undetected pregnancy.\n4. Non-childbearing potential is defined as follows (by other than medical reasons):\n\ni. ≥45 years of age and has not had menses for \\>1 year.\n\nii. Patients who have been amenorrhoeic for \\\u003C2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation.\n\niii. Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure.\n\n14\\. Male participants are eligible to participate if they agree to the following during the intervention period and for 6 months after the last dose of study treatment to allow for clearance of any altered sperm:\n\n1. Refrain from donating sperm\n\n   Plus, either:\n2. be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent\n\n   Or\n3. agree to use a barrier method of birth control (e.g., male condom), even if they have undergone a successful vasectomy, and female partner to use an additional highly effective contraceptive method with a failure rate of \\\u003C1% per year as when having sexual intercourse with a woman of childbearing potential (including pregnant females).\n\n   15\\. Patients with Human Immunodeficiency Virus (HIV) infection are eligible if:\n\na. patients without a history of Acquired Immune Deficiency Syndrome (AIDS)-defining opportunistic infections\n\nb. patients with a history of AIDS-defining opportunistic infection may be eligible if they have not had an opportunistic infection within past 12 months.\n\nc. Patients on active anti-retroviral therapy are eligible as long as anti-retroviral therapy is established for at least four weeks and have HIV viral load less than 400 copies\u002Fml prior to enrollment.\n\n16\\. Patients with chronic Hepatitis B Virus (HBV) infection or chronic Hepatitis C Virus (HCV) infection or virologically suppressed on HCV treatment are eligible if:\n\n1. Hepatitis B surface antigen (HBsAg)-negative, anti-Hemoglobin C (HBc)-positive patients are at lower risk of HBV reactivation compared with HBsAg-positive patients, risk of HBV reactivation should be considered in all patients and if patients can be on anti-HBV prophylaxis prior to initiation of anti-cancer therapy.\n2. Patients with chronic HBV infection with active disease who meet the criteria for anti HBV therapy should be on a suppressive antiviral therapy prior to initiation of cancer therapy.\n3. Patients actively on treatment for HCV should have HCV below the limit of quantification before initiation of anti-cancer therapy.\n4. Patients who are HCV antibody (Ab) positive but HCV Ribonucleic Acid (RNA) negative due to prior treatment or natural resolution of infection are eligible.\n\nExclusion Criteria:\n\n1. Patients previously treated for active symptomatic multiple myeloma.\n2. Any corneal disease except for mild epithelial punctate keratopathy.\n3. Patients with known immediate or delayed hypersensitivity reaction or idiosyncratic reactions to belantamab mafodotin or drugs chemically related to belantamab mafodotin, or any of the components of the study treatment.\n4. Patients eligible for autologous stem cell transplantation (ASCT).\n5. Evidence of significant cardiovascular condition as specified below:\n\n   1. N-terminal-prohormone of brain natriuretic peptide (NT-proBNP) ≥ 8500ng\u002FL within 14 days of registration.\n   2. New York Heart Association (NYHA) classification IIIB (3b) through IV (4) heart failure\n   3. Heart failure that in the opinion of the investigator is on the basis of ischemic heart disease (e.g., prior myocardial infarction with documented history of cardiac enzyme elevation and electrocardiogram (ECG) changes) or uncorrected valvular disease and not primarily due to AL amyloid cardiomyopathy\n   4. Unstable heart failure defined as emergency hospitalization for worsening, or decompensated heart failure, or syncopal episode within 1 month of screening\n   5. Subjects with a history of sustained ventricular tachycardia or aborted ventricular fibrillation or with a history of atrioventricular nodal or sinoatrial (SA) nodal dysfunction for which a pacemaker\u002Fimplantable cardioverter-defibrillator (ICD) is indicated but not placed (Subjects who do have a pacemaker\u002FICD are allowed on study)\n   6. Interval from the Q wave on the ECG to point T using Fredericia's formula (QTcF) \\> 500 msec. Subjects who have a pacemaker may be included regardless of calculated QTc interval\n   7. Symptomatic, clinically significant autonomic neuropathy which the Investigator feels will preclude administration of study treatment\n   8. Acute coronary syndrome, or any form of coronary revascularization procedure including coronary artery bypass grafting (CABG), within 6 months of screening\n   9. Prior solid organ transplant, or anticipated to undergo solid organ transplantation, or requiring left ventricular assist device (LVAD) implantation, during the course of the study\n   10. Stroke within 6 months of screening, or transient ischemic attack (TIA) within 3 months of screening\n   11. Evidence of current clinically significant uncontrolled arrhythmias, including clinically significant ECG abnormalities such as 2nd degree (Mobitz Type II) or 3rd degree atrioventricular (AV) block\n   12. History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within three (3) months of Screening\n   13. Uncontrolled hypertension\n6. Prior history of malignancy with the exception of the following: adequately treated basal cell or squamous cell skin cancer, curatively treated non-melanoma skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for at least two years.\n7. Presence of any comorbid or uncontrolled medical condition (e.g. uncontrolled hypertension) - defined as defined as an average SBP ≥ 160mm Hg or diastolic ≥ 100mm Hg despite optimal treatment) at screening, which in the opinion of the investigator would increase the potential risk to the subject.\n8. Unwillingness or inability to follow the procedures outlined in the protocol.\n9. Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 4 weeks or five half-lives, whichever is shorter, before Cycle 1 Day 1.\n10. Participant must not use contact lenses while participating in this study.\n11. Participant must not have had major surgery ≤ 4 weeks prior to initiating study treatment.\n12. Participant must not have any evidence of active mucosal or internal bleeding.\n13. Participant must not have any serious and\u002For unstable pre-existing medical, psychiatric disorder, or other conditions (including lab abnormalities) that could interfere with participant's safety, obtaining informed consent or compliance to the study procedures.\n14. Participants must not be pregnant or lactating.\n15. Participant must not be simultaneously enrolled in any interventional clinical trial.\n16. Participant must not have an active infection requiring treatment.\n17. Participant must not have current unstable liver or biliary disease defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. Note: Stable non-cirrhotic chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if otherwise meets entry criteria.","18 Years",{"count":55,"type":23},37,[57,58],"PHASE1","PHASE2","The goal of this study is to test the safety of drug, Belantamab Mafodotin, and see what effects (good and bad) it has on people who take it and have amyloidosis, and to determine the most effective dose of the drug.\n\nThe study will have 2 phases (parts). The first phase of the study will test different doses of Belantamab Mafodotin. The second phase will test Belantamab Mafodotin at the dose level found to be safe and effective in phase 1",[61,62],"AL Amyloidosis","Amyloidosis","RECRUITING",{"date":65,"type":38},"2026-08-19",{"date":67,"type":38},"2024-02-15",{"date":69,"type":23},"2027-09-01",{"name":44,"class":45},3,{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":24,"phases":82,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},"100428967","phase-3-gemcitabine-versus-water-irrigation-in-upper-tract-urothelial-carcinoma-100428967","NCT04865939","Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma","A Randomized Trial Comparing Intravesical Gemcitabine to Continuous Bladder Irrigation With Sterile Water to Prevent Bladder Cancer Implantation in Patients Undergoing Excision of Upper Tract Urothelial Carcinoma","Inclusion Criteria:\n\n* Biopsy proven UTUC with plan for excisional surgery (distal ureterectomy or nephroureterectomy) with curative intent\n* Age 18 - 90 years\n* Life expectancy \\> 1 year\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n* A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n\n  * Has not undergone a hysterectomy or bilateral oophorectomy; or\n  * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).\n* Ability to understand and the willingness to sign a written informed consent.\n\nExclusion Criteria:\n\n* Concurrent or prior diagnosis of bladder cancer with a disease-free interval of less than three years.\n* Synchronous bilateral upper tract urothelial carcinoma (prior history of contralateral UTUC is permissible with a disease-free interval of more than three years).\n* Plan for radical cystectomy.\n* Small bladder capacity (\\\u003C 100 mL).\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine or other agents used in study.","90 Years",{"count":81,"type":23},132,[83],"PHASE3","There is a high rate of intravesical (bladder) recurrence following extirpative surgery for upper tract urothelial carcinoma. There is no single established standard of care for prevention of intravesical recurrence; however, one protocol in common use involves the use of intravesical gemcitabine instilled into the bladder during surgery and prior to entry into the bladder. There are barriers to the use of gemcitabine, especially at lower volume centers. Some evidence suggests that intravesical irrigation with sterile water has equivalent efficacy to intravesical chemotherapy in prevention of recurrent bladder cancer following transurethral resection of bladder tumors (TURBT). This study is intended to compare recurrence rates using intravesical gemcitabine (as a pseudo-standard of care) and continuous bladder irrigation with sterile water.",[86,87],"Urothelial Cancer of Renal Pelvis","Urothelial Carcinoma Ureter","2026-08-13",{"date":35,"type":38},{"date":91,"type":38},"2021-11-29",{"date":93,"type":23},"2031-11-01",{"name":44,"class":45},1,{"id":97,"slug":98,"hasResults":12,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":12,"sex":18,"minAge":103,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":24,"phases":107,"briefSummary":108,"conditions":109,"keywords":114,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":135},"100650944","importance-of-point-of-care-ultrasound-for-early-detection-of-valvular-and-cardiac-diseases-improve-100650944","NCT07756398","Importance of Point-of-Care Ultrasound for Early Detection of Valvular and Cardiac Diseases (IMPROVE)","IMPROVE","Inclusion Criteria:\n\nProvider (cluster) participants:\n\n* Physician or advanced practice provider (physician assistant or nurse practitioner) practicing in primary care or geriatrics at a participating institution who independently assesses patients\n* Patient panel comprising \\>50% adults aged 65 years or older\n* Sees patients in ambulatory clinic at least 1 day per week on average\n* Agrees to participate, to undergo randomization, and to permit inclusion of all eligible patients from the panel\n* Provides written informed consent\n\nPatient participants:\n\n* Adults aged 65 to 85 years, inclusive\n* Attending a scheduled outpatient visit at a participating geriatrics or primary care clinic\n* Willing and able to provide written informed consent and, if the AI-POCUS screen is positive, to return for a confirmatory echocardiogram\n\nExclusion Criteria:\n\nProvider (cluster) participants:\n\n* Serving in a locum tenens or other temporary capacity\n* Unwilling or unable to nominate an AI-POCUS champion from the clinic\n\nPatient participants:\n\n* Echocardiogram performed within the past 5 years\n* At least moderate aortic or mitral valve disease, or left ventricular ejection fraction 50% or less, documented on any prior echocardiogram\n* History of surgical or transcatheter intervention for aortic or mitral valve disease\n* Self-reported structural heart disease\n* Significant frailty burden or comorbidities limiting life expectancy to\n\n  1 year or less\n* Unable to provide informed consent","65 Years","85 Years",{"count":106,"type":23},1088,[26],"Heart valve disease and weakened heart muscle (left ventricular systolic dysfunction) are common in older adults and often go undetected until serious complications such as heart failure develop. Detection currently depends on a clinician hearing a murmur and then ordering an echocardiogram, which is easily missed or delayed.\n\nThis study tests whether a brief, artificial intelligence (AI)-guided handheld heart ultrasound - point-of-care ultrasound, or POCUS - performed by trained clinic staff during a routine visit identifies these conditions earlier than usual care.\n\nPrimary care and geriatrics providers, rather than individual patients, are assigned by chance to one of two groups. Patients seen by providers in the AI-ultrasound group are offered a POCUS scan and a one-time blood test at their regular visit, and are referred for a confirmatory echocardiogram if the scan is abnormal. Patients seen by providers in the usual care group receive standard clinic care. Researchers will compare how often previously undiagnosed structural heart disease is newly identified in each group.",[110,111,112,113],"Valvular Heart Disease Patients","Aortic Stenosis","Mitral Regurgitation","Left Ventricular Diastolic Dysfunction",[115,116,117,118,119,120,121,122,123,124,125,126,127],"Point-of-care ultrasound","POCUS","Artificial Intelligence","AI-guided imaging","Echocardiography","Screening","Early detection","Heart Failure","Older Adults","Geriatrics","Primary Care","Cluster randomized Trial","Implementation Science","2026-08-12",{"date":35,"type":38},{"date":131,"type":23},"2026-08-01",{"date":133,"type":23},"2028-12-01",{"name":44,"class":45},2,{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":24,"phases":146,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":95},"100603705","phase-1-personalized-radiotherapy-for-individualized-treatment-strategies-and-monitoring-prism-100603705","NCT07139990","Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)","Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM): A Multi-cohort Platform Trial of Adaptive Radiotherapy Approaches in Multiple Cancer Types","PRISM","Inclusion Criteria:\n\nCohort A:\n\n* \\>=18 years old\n* Performance status ECOG 0-2\n* Extensive stage small cell lung cancer diagnosed by tissue biopsy within 180 days of registration.\n* Patient must be planned for or receiving standard of care chemoimmunotherapy.\n* Patient must have received no more than 3 cycles by time of study enrollment.\n* Able and indicated according to investigator to receive thoracic radiotherapy\n\nCohort B:\n\n* 18 years old\n* Diagnosis of solid tumor malignancy with MRI-defined brain metastasis lesions within 60 days of registration\n* Each brain metastasis lesion enrolled must be 2 - 5 cm, except brainstem lesions which may be 1.5 - 5cm in size.\n\nCohort C:\n\n* \\>=18 years old\n* Performance status ECOG 0-2\n* Histologically confirmed surgically resectable, high grade (FNCLCC grade 2 or 3), localized soft tissue sarcoma of the trunk or extremities that measures \\>5 cm in any direction as assessed by imaging\n* Eligible to receive immunotherapy\n\nCohort D:\n\n* \\>=18 years old\n* Performance status ECOG 0-2\n* Pathologically proven diagnosis of squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx\n* Clinical stage III\u002FIVA (AJCC 8th edition)\n* Disease must be deemed resectable by head and neck surgeon\n* Eligible to receive immunotherapy\n\nExclusion Criteria:\n\nCohort A:\n\n⨀ Prior thoracic Radiotherapy\n\nCohort B:\n\n* Prior whole brain Radiotherapy\n* Prior surgical resection or focal radiotherapy of a target brain metastasis\n* Leptomeningeal disease\n\nCohort C:\n\n* Unresectable or metastatic (nodal or distant) disease\n* Synchronous malignancy requiring chemotherapy or other intensive treatment\n* Locally recurrent soft tissue sarcoma\n* Prior immunotherapy\n* Pregnancy or breastfeeding\n\nCohort D:\n\n* Distant metastasis\n* Inability to undergo PET-CT for baseline staging\n* HPV-positive or p16-positive oropharyngeal cancer\n* Prior systemic chemotherapy for the study cancer; prior chemotherapy for a remote cancer is allowable\n* Prior immunotherapy for the study cancer or for a remote cancer\n* Prior head and neck radiotherapy",{"count":145,"type":23},105,[57],"To characterize feasibility, safety, and\u002For preliminary efficacy of personalized strategies to adapt standard radiotherapy treatments to individual patient responses.",[149,150,151,152,153,154],"Small Cell Lung Cancer Extensive Stage","Brain Metastases","Solid Tumor, Adult","Thoracic Cancer","Sarcoma,Soft Tissue","HNPCC",{"date":35,"type":38},{"date":157,"type":38},"2025-10-28",{"date":159,"type":23},"2032-09-01",{"name":44,"class":45},{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":104,"enrollmentInfo":168,"targetDuration":4,"studyType":24,"phases":170,"briefSummary":172,"conditions":173,"keywords":178,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":189},"100522562","phase-4-national-liver-cancer-screening-trial-100522562","NCT06084234","National Liver Cancer Screening Trial","TRACER","Inclusion Criteria:\n\nPatient must meet all of the following inclusion criteria:\n\n1. Adult patients ages 18-85 with cirrhosis from any etiology or with chronic hepatitis B with a PAGE-B score greater than 9 within 12 months of enrollment\n2. Patient is eligible for HCC surveillance according to treating physician or by the site investigator\n3. Able to provide informed consent\n4. Life expectancy \\>6 months (after consent) as determined by the treating provider or site investigator\n\nExclusion Criteria:\n\nPatient will be excluded for any of the following exclusion criteria:\n\n1. Child Pugh C cirrhosis\n2. History or clinical symptoms of hepatocellular carcinoma or cholangiocarcinoma\n3. History of solid nodule on baseline ultrasound (i.e., lesion 1cm or greater) within 9 months prior to consent without subsequent diagnostic CT\u002FMRI demonstrating benign nature)\n4. AFP \\>20 ng\u002FmL within 6 months prior to consent, in the absence of a contrast-enhanced CT or MRI within 6 months of AFP (before or after) level demonstrating lack of suspicious liver lesions\n5. Newly diagnosed LR-3 greater than or equal to 1 cm within 6 months prior to consent\n6. History of LR-4, LR-5, or LR-M on multi-phase CT or contrast-enhanced MRI within 6 months prior to consent\n7. Presence of another active cancer besides non-melanomatous skin cancer or indolent cancer under active surveillance (e.g., prostate cancer or renal cell carcinoma) within the 2 years prior to consent\n8. Patient's provider is planning to use MRI- or CT- based surveillance moving forward\n9. History of a transjugular intrahepatic portosystemic shunt (TIPS)\n10. History of Fontan associated liver disease or cardiac cirrhosis\n11. History of solid organ transplantation\n12. Actively listed for liver transplantation\n13. Diagnosis of alcohol-associated hepatitis within 3 months prior to consent\n14. Documented current or continued signs and symptoms of acute Wilson disease (acute liver failure, acute neurological deficits, hemolysis)\n15. In patients with primary sclerosing cholangitis (PSC): Current active cholangitis within 90 days prior to consent\n16. Known or documented habitual non-adherence to previous research studies or medical procedures or unwillingness to adhere to protocol (e.g., unwilling to obtain consent or samples)\n17. In patients living with HIV: CD4+ T cell count less than 100 cells\u002Fmm3 within 60 days prior to consent\n18. Known pregnancy at consent\n19. Active warfarin use",{"count":169,"type":23},5500,[171],"PHASE4","The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients with cirrhosis from any etiology or patients with chronic hepatitis B infection. Eligible patients will be randomized in a 1:1 fashion to Arm A using semi-annual ultrasound and AFP-based screening or Arm B using semi-annual screening using GALAD alone. Randomization will be stratified by sex, enrolling site, Child Pugh class (A vs. B), and HCC etiology (viral vs. non-viral). Patients will be recruited from 15 sites (mix of tertiary care and large community health systems) over a 3-year period, and the primary endpoint of the phase IV trial, reduction in late-stage HCC, will be assessed after 5.5 years.",[174,175,176,177],"Carcinoma, Hepatocellular","Liver Cancer","Liver Cirrhosis","Hepatitis B",[179,180,181],"Hepatocellular carcinoma surveillance","GALAD","Alpha Fetoprotein","2026-08-10",{"date":128,"type":38},{"date":185,"type":38},"2023-12-26",{"date":187,"type":23},"2034-12-31",{"name":44,"class":45},19,{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":24,"phases":199,"briefSummary":200,"conditions":201,"keywords":203,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":135},"100651361","food-as-medicine-to-reduce-ckd-burden-in-health-disparity-populations-100651361","NCT07759401","Food As Medicine to Reduce CKD Burden in Health Disparity Populations","FAME-CKD","Inclusion Criteria:\n\n* men and women of age ≥ 18 years and able to give consent;\n* willingness to participate in a 12-month study;\n* elevated albumin to creatinine ratio (ACR) (≥ 30 mg\u002Fg) determined by point-of-care urine dipstick during health screen;\n* Reside in a low-income area or visit a food pantry due to food insecurity\n\nExclusion Criteria:\n\n* whose urine dipstick does not indicate micro- or macro-albuminuria (ACR \\\u003C30 mg\u002Fg),\n* currently receiving dialysis or need dialysis,\n* have received or need a kidney transplant,\n* pregnant or plan to become pregnant in the next 12 months,\n* baseline urine potassium \\> 60 mEq\u002Fg creatinine (baseline excretion below this level was not associated with hyperkalemia when fruit\u002Fvegetable were paired with kidney-protective drugs,\n* urine ACR values indicate nephrotic proteinuria, and\n* CKD stage 5 demonstrated by elevated estimated glomerular filtration rate (eGFR) obtained during baseline measures.",{"count":198,"type":23},500,[26],"Healthy eating plays an important role in kidney and heart health, and programs that use food as medicine can help improve diet and overall health, but the best ways to support healthy eating in community settings are not well understood. The purpose of this study is to compare two study groups to see which is more effective at improving kidney health and related health outcomes in adults with chronic kidney disease. One group receives fruits and vegetables with cooking education, and the other receives fruits and vegetables alone. The results may help researchers develop community-based programs to improve kidney and heart health, especially in populations at higher risk for kidney disease.\n\nIf the participant joins the study, the participant will complete a baseline visit, a 6-month visit, and a 12-month visit. Visits include questionnaires about the participant's health, diet, and cooking habits; a urine sample; a blood sample; blood pressure, height, weight, and waist measurements; and a brief, painless Veggie Meter® scan to measure fruit and vegetable intake. Participants will pick up weekly fruits and vegetables for 12 months. Those in the cooking group will also attend 12 weekly cooking and nutrition classes and receive follow-up newsletters and optional monthly virtual sessions. Depending on the group to which the participants are assigned, the total time commitment for the participants in this study will range from approximately 3 to 15 hours.\n\nParticipation is voluntary, involves minimal risk, and all information will be kept private. Possible risks include brief pain or bruising from the blood draw, mild discomfort from urine collection, minor risk of cuts or burns during cooking, and some questions may feel personal; the participant may skip any question. There may be no direct benefit to the participant, but the participant's participation may help improve nutrition and kidney health programs in the community.",[202],"Chronic Kidney Disease",[202,204,205],"CKD","Food is Medicine","2026-08-06",{"date":128,"type":38},{"date":209,"type":23},"2026-10",{"date":211,"type":23},"2032-10",{"name":44,"class":45},{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":18,"minAge":221,"maxAge":222,"enrollmentInfo":223,"targetDuration":4,"studyType":24,"phases":225,"briefSummary":226,"conditions":227,"keywords":230,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":236,"completionDateStruct":237,"leadSponsor":239,"locationsCount":95},"100595270","comparing-surfactant-administration-through-supraglottic-airway-and-thin-catheter-for-preterm-infants-100595270","NCT07030270","Comparing Surfactant Administration Through Supraglottic Airway and Thin Catheter for Preterm Infants","A Clinical Trial Comparing Surfactant Administration Through Supraglottic Airway or Thin Catheter for Preterm Infants","SALTI","Inclusion Criteria:\n\n* All preterm infants born at or greater than 29 weeks' gestational age\n* Infants with birthweight greater than or equal to 750 grams and admitted to the NICU on CPAP for respiratory support and qualify for LISA procedure\n\nExclusion Criteria:\n\n* Infants who require intubation prior to surfactant therapy\n* Infants with known severe congenital anomalies (complex congenital heart disease, airway and central nervous system anomalies)\n* Infants whose birth weight is less than 750 grams or oropharynx unable to accommodate laryngeal mask airways","0 Hours","72 Hours",{"count":224,"type":23},40,[26],"What is this study about? This study is comparing two ways of giving surfactant, a medicine that helps premature infants breathe better. Surfactant can be given using a thin tube (\"Less Invasive Surfactant Administration\", called the LISA method) or through a small airway device placed in the baby's throat (\"Surfactant Administration through Laryngeal or Supraglottic Airway\", called the SALSA method). The goal is to see which method is safer and more effective for infants who are born at or after 29 weeks of pregnancy and have trouble breathing.\n\nWhat is the main question (hypothesis)? Infants who receive surfactant using the SALSA method will have fewer breathing-related problems and fewer short-term complications than those who receive it using the LISA method.\n\nWhat are the aims? Aim 1: Are babies in the SALSA group less likely to have low heart rate or low oxygen levels during the procedure compared to babies in the LISA group? Aim 2: Do fewer babies in the SALSA group need to be put on a breathing machine within the first 72 hours of life? Aim 3: Does the SALSA method help reduce the overall time babies need breathing support and lower the cost of their care in the NICU?",[228,229],"Surfactant","Respiratory Distress Syndrome (Neonatal)",[231,232,233],"preterm infants","surfactant therapy","respiratory distress syndrome","2026-08-05",{"date":182,"type":38},{"date":234,"type":38},{"date":238,"type":23},"2030-08",{"name":44,"class":45},{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":12,"sex":18,"minAge":248,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":24,"phases":251,"briefSummary":252,"conditions":253,"keywords":257,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":95},"100650880","support-and-healing-intervention-for-adolescents-with-a-parent-diagnosed-with-cancer-shine-100650880","NCT07751185","Support and Healing Intervention for Adolescents With a Parent Diagnosed With Cancer (SHINE)","Support and Healing Intervention for Navigating Parental Cancer Experiences (SHINE): A Mixed-Methods Study to Develop and Pilot-Test a Family-Centered Psychosocial Intervention for Adolescents With a Parent Diagnosed With Cancer","SHINE","Inclusion Criteria:\n\nParent or caregiver aged 18 years or older with a documented diagnosis of Stage I-IV (or equivalent) cancer.\n\nParent or caregiver has at least one adolescent child between the ages of 10 and 17 years living in the household.\n\nParent\u002Fcaregiver and adolescent are able to communicate in English or Spanish. Parent or caregiver is willing and able to provide informed consent, and the adolescent is willing and able to provide assent.\n\nFamily is willing and able to participate in study procedures, including intervention sessions and study assessments.\n\nExclusion Criteria:\n\nAdolescent younger than 10 years or older than 17 years. Parent\u002Fcaregiver or adolescent unable to communicate in English or Spanish. Parent\u002Fcaregiver or adolescent with significant cognitive impairment or developmental delay that would prevent meaningful participation in study procedures.\n\nFamily unable or unwilling to complete study procedures or follow-up assessments.\n\nParent\u002Fcaregiver unwilling or unable to provide informed consent, or adolescent unwilling or unable to provide assent.","10 Years",{"count":250,"type":23},80,[26],"e purpose of this study is to develop and evaluate SHINE (Support and Healing Intervention for Navigating Parental Cancer Experiences), a family-centered program designed to support adolescents whose parent has been diagnosed with cancer.\n\nThe study has two phases. In the first phase, parents and adolescents will participate in interviews or focus groups to help researchers understand their experiences and identify the types of support that families need. Information from these discussions will be used to refine the SHINE program.\n\nIn the second phase, families will be randomly assigned to either receive the SHINE program or continue with their usual supportive care. The SHINE program consists of approximately four sessions delivered over 8 weeks and focuses on improving communication, coping skills, resilience, and emotional well-being. Adolescents will complete questionnaires before the program begins, immediately after the 8-week intervention period, and 3 months later.\n\nResearchers will evaluate whether SHINE is feasible to deliver, acceptable to families, and shows promise for improving psychosocial outcomes among adolescents coping with a parent's cancer diagnosis.",[254,255,256],"Cancer","Psychological Distress","Adaptation, Psychological",[258,259,260,261,262,263,264,265,266,267,268,269,270,271,246],"Parental cancer","Adolescents","Family-centered intervention","Psychosocial intervention","Supportive care","Cancer survivorship","Family communication","Coping","Resilience","Peer support","Pediatric psychosocial oncology","Behavioral intervention","Mixed-methods","Randomized controlled trial","2026-07-31",{"date":274,"type":38},"2026-08-07",{"date":276,"type":23},"2026-09-01",{"date":278,"type":23},"2029-12-31",{"name":44,"class":45},{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":24,"phases":289,"briefSummary":290,"conditions":291,"keywords":292,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":299,"leadSponsor":301,"locationsCount":95},"100635246","oncology-acute-care-follow-up-intervention-study-100635246","NCT07550192","Oncology Acute Care Follow-up Intervention Study","A Pragmatic Randomized Controlled Crossover Study to Evaluate the Impact of Messaging Interventions on Emergency Department Utilization Among Oncology Patients at Parkland Health","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Active cancer diagnosis\n* Actively receiving chemotherapy treatment\n* ED Arrival within 30 days of chemotherapy treatment\n* Discharged home following ED visit, observation, or inpatient stay\n* Enrolled in MyChart with valid mobile number and language preference recorded (English or Spanish)\n\nExclusion Criteria:\n\n* Not enrolled in MyChart or lacking a valid mobile phone number.\n* Language preference not recorded or not English\u002FSpanish (if messaging is only available in these languages).\n* Receiving hospice or palliative care services, where acute symptom management goals may differ.\n* Patients admitted directly to inpatient care without ED visit",{"count":288,"type":23},200,[26],"This pragmatic randomized controlled study evaluates an education intervention designed to increase patient engagement with Oncology Acute Care (OAC) services among patients being treated for cancer at Parkland Health.\n\nEligible patients will be randomized to either a control (usual care) arm or an intervention arm. If a patient in the control group has experiences a subsequent cancer treatment related ED visit without documented OAC engagement, they will be moved to the intervention arm. Patients in the intervention arm will receive an automated MyChart message and text message within 24 hours of hospital discharge reinforcing oncology acute care (OAC) resources, including contact information for the triage line and guidance for when to seek urgent versus emergency care. Messages will be resent at 48 and 72 hours if unviewed. Once the message is viewed, the patient will enter an outcome tracking period to monitor time to subsequent ED visit or OAC contact. Follow-up will occur in 3-month intervals until an outcome is documented or the study ends.\n\nAfter randomization, patients will be monitored on an observation list for outcomes including OAC contact and cancer treatment-related Emergency Department (ED) visits. Patients who contact OAC clinic will be removed from observation list and complete the study. We will repeat the observation period and document outcomes if the patient has a subsequent cancer treatment-related ED visits without documented OAC engagement.",[254],[293,294,295],"Oncology Acute Care","Emergency Department Use","Messaging",{"date":297,"type":38},"2026-08-04",{"date":276,"type":23},{"date":300,"type":23},"2028-12-31",{"name":44,"class":45},{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":310,"enrollmentInfo":311,"targetDuration":4,"studyType":24,"phases":312,"briefSummary":313,"conditions":314,"keywords":317,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":321,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":95},"100527115","phase-1-polypill-for-prevention-of-cardiomyopathy-100527115","NCT06143566","Polypill for Prevention of Cardiomyopathy","Polypill Strategy for Prevention of Cardiomyopathy Among Patients With Diabetes at Risk of Heart Failure","PolyPreventHF","Inclusion Criteria:\n\n* Patients with Type 2 DM\n* History of chronic kidney disease, defined as an estimated glomerular filtration rate (eGFR) of 25 to 90 per minute per 1.73 m2 of body-surface area (stage 2 to 4 CKD) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of less than 5000\n* With either a: High risk of HF as defined by High Watch-DM score (≥11) or Elevated natriuretic peptides or Diastolic dysfunction or left ventricular hypertrophy on echocardiography\n\nExclusion Criteria:\n\n* eGFR \\\u003C 25\n* Congestive heart failure\n* Hyperkalemia \\> 5.0\n* Contraindication to any component of polypill\n* Pregnancy\n* Creatinine \\>2.0mg\u002FdL in men and \\>1.8mg\u002FdL in women\n* Inability to calculate WATCH-DM score\n* Inability to undergo exercise testing","100 Years",{"count":288,"type":23},[57,58],"This study will investigate the utility of a polypill-based strategy for patients with type 2 diabetes mellitus and high risk of heart failure (HF), as assessed via the WATCH-DM risk score. Polypill therapy will consist of empagliflozin 12.5 mg, losartan 25, 50 or 100 mg, and finerenone 10 mg daily. The study duration is 6 months, and participants will be randomized to either polypill therapy or simultaneous prescription of the individual drugs. The primary outcome is change in peak VO2 and adherence to usual care. The investigators hypothesize that the use of a polypill is feasible and improves medication adherence and peak VO2 as compared to those receiving usual care.",[315,316],"Type 2 Diabetes","High Blood Pressure",[315,318,319,320],"Diabetic Cardiomyopathy","Hypertension","Polypill",{"date":297,"type":38},{"date":323,"type":38},"2024-03-11",{"date":325,"type":23},"2027-12-01",{"name":44,"class":45},{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":334,"targetDuration":4,"studyType":336,"phases":4,"briefSummary":337,"conditions":338,"keywords":342,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":345,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":135},"100521972","petmr-for-characterization-of-renal-masses-rms-100521972","NCT06076538","PET\u002FMR for Characterization of Renal Masses (RMs)","Prospective Observational Study Using PET\u002FMR for Characterization of Renal Masses (RMs)","Inclusion Criteria:\n\n* Patients with known solid (\\>25% total volume enhances) renal mass\n* Renal mass size measuring \\>2 to ≤7 cm\n* Age \\>18 years\n* Ability to understand and the willingness to sign a written informed consent.\n\nExclusion Criteria:\n\n* Pregnancy\n* Prior percutaneous biopsy of the renal mass\n* Prior treatment of the renal mass\n* Prior hemorrhage in the renal mass\n* Contraindication to MRI or PET\n* Renal mass not eligible for ccLS based on prior imaging (i.e., containing macroscopic fat \\[classic angiomyolipoma\\] or enhancing less than 25% of its volume \\[considered a cystic renal mass\\])\n* Genetic syndrome predisposing to renal masses (e.g., VHL, BHD, TSC, etc.);\n* More than 3 renal masses at time of initial diagnosis",{"count":335,"type":23},97,"OBSERVATIONAL","The frequency of kidney tumors found incidentally on imaging studies performed for unrelated reasons continues to increase leading to more surgeries and ablations for the treatment of renal masses thought to be cancer. However, about 20% of these masses are not cancerous and do not require treatment. Many cancerous kidney tumors are indolent and can be followed safely with imaging (i.e., particularly tumors \\\u003C2 cm and in patients with limited life expectancy), while some tumors are both malignant and aggressive, with a higher potential to spread outside the kidney and require treatment.\n\nThe purpose of this observational study is to assess the ability of Fludeoxyglucose (18F) (FDG) PET\u002FMR to distinguish different types of kidney tumors. The investigators hypothesize that PET\u002FMR will better show differences between aggressive and both indolent and benign kidney masses compared to the currently used radiologic scans.\n\nParticipants will be selected from those who have been scheduled to receive a contrast-enhanced MRI for their regular care due to a suspicious kidney mass. Participants will have their MRI on a hybrid PET\u002FMR scanner capable of obtaining both MRI and PET images. While they are receiving their standard of care MRI exam, patients will also receive a research FDG PET exam. Participants will have an IV placed for administration of the MRI contrast agent, just as they would if they were not taking part in the study. The same IV will be used to give the FDG radiopharmaceutical for the PET scan and furosemide (a diuretic), to help empty the bladder before the scan and help better see the kidneys on the scans. Both FDG and furosemide are FDA approved medications. Participants will have only one visit with the research team which will last \\~2.5 hours and will include collection of the participant's regularly scheduled MRI.\n\nIf participants undergo surgery to remove the tumor, the study will collect samples of the removed tissue for research. If participants receive a biopsy of the tumor, the study may collect an additional sample of the tumor for research.\n\nAfter the PET\u002FMRI, participants will not have additional visits with the study team, but the study team may call every 6-12 months for up to 2 years to see how they are doing and ask about their health. The study team will review the medical record for any changes to their diagnosis, updates to their medical history, new scans ordered by their regular doctor, or recent lab or biopsy results.",[339,340,341],"Renal Tumor","Renal Cell Carcinoma","Renal Tumor, Benign",[343,340,344],"Renal Mass","PET\u002FMR",{"date":297,"type":38},{"date":347,"type":38},"2023-08-01",{"date":349,"type":23},"2028-06-01",{"name":44,"class":45},{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":17,"sex":18,"minAge":53,"maxAge":358,"enrollmentInfo":359,"targetDuration":4,"studyType":336,"phases":4,"briefSummary":361,"conditions":362,"keywords":365,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":4},"100650069","the-cardiovascular-effects-of-patent-foramen-ovale-in-hypoxia-100650069","NCT07742540","The Cardiovascular Effects of Patent Foramen Ovale in Hypoxia","The Role of Patent Foramen Ovale on Cardiac Hemodynamics and Exercise Cardiac Reserve in HAPE-susceptible Individuals","Inclusion Criteria:\n\n* Males and females age \\> 18 but \\\u003C 60 years of age at the time of signing the informed consent.\n* Medically documented episode of noncardiogenic pulmonary edema occurring after exposure to hypoxia at high altitude.\n* No other associated congenital cardiac or vascular abnormalities.\n* Physically active, and able to perform endurance exercise.\n\nExclusion Criteria:\n\n* Do not otherwise meet the inclusion criteria.\n* Cardiac- or pulmonary-related medications.\n* Known history of anemia, iron deficiency, iron supplementation (oral or intravenous) in the preceding 60 days.\n* Systemic anticoagulation or aspirin use that cannot be temporarily held for the study.\n* Non-cardiopulmonary disorders that adversely influence exercise ability (e.g. arthritis or peripheral vascular disease).\n* Engaging in vigorous physical activity \\[≥1 hour at ≥6 mets\\] at ≥8,000 ft for \\>2 days per week over the preceding 4 weeks, and residing at ≥8,000 ft for 3 or more consecutive nights in the preceding 30 days.\n* History of any recent illnesses (e.g. viral respiratory infections) within 4 weeks of testing.\n* Women who are pregnant (urine pregnancy test given to all women of childbearing age at the time of testing).\n* Other conditions that would limit the patient's ability to complete the study procedures.","60 Years",{"count":360,"type":23},50,"Before birth, the foramen ovale is a normal opening in the heart that allows blood to flow from the mother to the baby. After birth, this opening usually closes. However, in up to 38% of the population it does not fully close and is then called a patent foramen ovale (PFO). Having a PFO allows venous (blue) blood to mix with arterial (red) blood in the heart, which can lower blood oxygen levels. The mixing of blood has been suggested to be greater during exercise and with exposure to high-altitude. Also, people with a PFO may be a greater risk for severe altitude sickness, specifically involving the collection of fluid in the lungs which makes breathing very difficult - this is called high-altitude pulmonary edema (HAPE).\n\nNo study has directly measured the pressure difference across the heart which is required for the mixing of blood during exercise or at high-altitude. The present study will directly measure the pressure difference across the heart, as well as blood flow through the PFO during rest and exercise in simulated high altitude in adults with and without a PFO and a previous history of severe altitude sickness. The study will test the hypothesis that elevations in pulmonary artery pressure during exposure to hypoxia will not elicit a pressure gradient, and thus blood flow, across the PFO neither at rest nor during exercise.",[363,364],"Patent Foramen Ovale (PFO)","High Altitude Pulmonary Edema",[366,367,368,369,370,371,372,373,374],"hypoxia","altitude","heart","high altitude pulmonary edema","patent foramen ovale","exercise","pulmonary artery pressure","intracardiac pressures","right-to-left shunt","2026-07-28",{"date":377,"type":38},"2026-08-03",{"date":379,"type":23},"2026-09-15",{"date":381,"type":23},"2028-09-15",{"name":44,"class":45},{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":17,"sex":18,"minAge":53,"maxAge":390,"enrollmentInfo":391,"targetDuration":4,"studyType":24,"phases":393,"briefSummary":394,"conditions":395,"keywords":398,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":95},"100609872","venous-compression-in-fontan-100609872","NCT07220226","Venous Compression in Fontan","Venous Function and the Effect of Venous Compression on Exercise Cardiovascular Function in Patients With Fontan Circulation.","Patients with a Fontan circulation -\n\nInclusion criteria:\n\n• Patients at UTSW aged 18-45 years old with a Fontan circulation.\n\nExclusion Criteria:\n\n* NYHA Class 4\n* Severe AV valve regurgitation\n* Severe ventricular dysfunction\n* Large ascites\n* Significant varicosities\n* Atrio-pulmonary (AP) Fontan\n* Known Fontan thrombus\n* Poorly controlled arrythmia\n* Unplanned cardiac admission in the last 6 months\n* Cyanosis (resting O2 saturation \\\u003C85%)\n* Pregnant\n* Common femoral vein obstruction \\>50% to be performed following completion of informed consent.\n\nHealthy Controls:\n\nHealthy control participants will be recruited on the basis of having no known chronic diseases and not currently taking any cardiovascular medications.","45 Years",{"count":392,"type":23},20,[26],"The aim of this study is to investigate whether venous compression garments increase exercise stroke volume in patients with Fontan circulation. To address this aim, we will test the following hypotheses:\n\n1. Acute and chronic external venous compression will increase exercise stroke volume in patients with Fontan circulation.\n2. Patients with significant venous varicosities will have a greater response to venous compression.\n\nParticipants will:\n\n* Undergo submaximal exercise testing in MRI to measure venous return and exercise stroke volume with and without the wearing of compression garments\n* Undergo submaximal exercise testing on a seated upright exercise ergometer with concurrent measurement of stroke volume with and without the wearing of compression garments\n* A subset of participants will repeat both testing visits after wearing compression garments for 2-weeks during waking hours.\n\nParticipants will:\n\n* Undergo submaximal exercise testing in MRI to measure venous return and exercise stroke volume with and without the wearing of compression garments\n* Undergo submaximal exercise testing on a seated upright exercise ergometer with concurrent measurement of stroke volume with and without the wearing of compression garments\n* A subset of participants will repeat both testing visits after wearing compression garments for 2-weeks during waking hours.",[396,397],"Single-ventricle","Fontan Circulation",[399,400,401,397,402,403],"Venous Compression","Exercise Testing","Cardiac Reserve","Magnetic Resonance Imaging","vascular function",{"date":405,"type":38},"2026-07-30",{"date":407,"type":38},"2026-05-10",{"date":409,"type":23},"2027-11-01",{"name":44,"class":45},{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":418,"minAge":53,"maxAge":104,"enrollmentInfo":419,"targetDuration":4,"studyType":24,"phases":421,"briefSummary":422,"conditions":423,"keywords":426,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":135},"100585809","phase-1-daily-nitrofurantoin-versus-bladder-fulguration-plus-daily-nitrofurantoin-for-women-with-recurrent-urinary-tract-infections-100585809","NCT06907199","Daily Nitrofurantoin Versus Bladder Fulguration Plus Daily Nitrofurantoin for Women With Recurrent Urinary Tract Infections","A Multicentric Randomized Trial of Daily Nitrofurantoin Versus Bladder Fulguration Plus Daily Nitrofurantoin for the Long-term Management of Cystitis in Women With Recurrent Urinary Tract Infections","Inclusion Criteria:\n\n* Females 18 to 85 years old with at least a 1-year history of culture documented uncomplicated rUTI.\n* Diagnosis of rUTI, defined as ≥ 3 symptomatic UTIs in 12 months or ≥ 2 in 6 months.\n* Currently free from a UTI determined based on absence of symptoms as determined by the UTI symptom assessment questionnaire and negative urine culture (\\\u003C10\\^3 colony forming units per ml of urine).\n* A negative upper and lower urinary tract evaluation, including pelvic examination for pelvic organ prolapse (less than or equal to stage 2), measurement of post-void residual (less than 50 ml), and imaging (which may include renal ultrasound and standing voiding cystourethrogram) to exclude kidney stone, hydronephrosis, reflux, or urethral diverticulum.\n* Office cystoscopy documenting stages 1 or 2 of chronic cystitis.\n* Likely to stay in the geographic region for the duration of the study.\n* ASA class II or less.\n\nExclusion Criteria:\n\n* Patients on antibiotics at baseline (i.e., suppressive therapy or antibiotic therapy for non-urinary infections).\n* Patients on self-start therapy (i.e., taking antibiotics upon start of urinary symptoms concerning for UTI).\n* Patients on prophylactic antibiotics started in the last 3 months and unwilling to discontinue, or intention to start in the next 12 months.\n* Complicated UTIs, including neurogenic bladder condition (i.e., multiple sclerosis, Parkinson's disease, spinal cord injury), bladder augmentation, or urinary diversion.\n* Patients with urinary catheters (including indwelling Foley, intermittent catheterization, and suprapubic catheters).\n* Uncontrolled diabetes (HbA1c \\>9).\n* Pregnancy\n* Allergy or resistance to Nitrofurantoin.\n* Chronic lung or liver condition precluding the use of Nitrofurantoin, including abnormal chest X ray or elevated liver function tests.\n* Chronic renal insufficiency (creatinine over 1.5 g\u002Fdl or GFR less than 40) precluding the use of Nitrofurantoin.\n* History of chronic diarrhea requiring regular therapy.\n* Patients with psychosis, dementia, swallowing disorders, or any other ability to take Nitrofurantoin reliably at home.\n* BMI over 40.\n* Use of Uromune or other vaccine approaches to reduce rUTI episodes\n* Participation in a research study involving an investigational product in the past 12 weeks.\n* Patients receiving phage therapy.\n* Current diagnosis of interstitial cystitis.\n* Patients with medical conditions requiring excessively large amounts of fluid intake.","FEMALE",{"count":420,"type":23},104,[57],"The goal of this clinical trial is to learn if the drug Nitrofurantoin (NF) taken as a daily antibiotic, works to treat cystitis compared to electrofulguration (EF) and Nitrofurantoin (NF) daily antibiotic.",[424,425],"Recurrent UTIs","Cystitis Recurrent",[427,428,429,430,431],"bladder fulguration","Nitrofurantoin","long-term managenent of cystitis","Recurrent UTI","chronic UTI","2026-07-22",{"date":434,"type":38},"2026-07-23",{"date":436,"type":38},"2026-04-06",{"date":438,"type":23},"2029-01-30",{"name":44,"class":45},{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":444,"acronym":445,"eligibilityCriteria":446,"healthyVolunteers":12,"sex":447,"minAge":53,"maxAge":4,"enrollmentInfo":448,"targetDuration":4,"studyType":24,"phases":450,"briefSummary":452,"conditions":453,"keywords":458,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":95},"100644944","early-phase-1-response-with-interim-psma-pet-in-metastatic-castration-sensitive-prostate-cancer-for-optimization-of-adaptive-metastasis-directed-radiotherapy-delivery-100644944","NCT07674771","Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery","RIPCORD","Inclusion Criteria:\n\n1. History of pathologically confirmed prostate cancer.\n2. Age \\>=18 years.\n3. Performance status ECOG 0-2.\n4. Staging 68Ga PMSA-11 PET\u002FCT showing 4-20 sites of metastasis from prostate cancer within \\\u003C=90 days prior to registration. This scan ideally should be performed before initiation of androgen deprivation therapy (ADT).\n5. At the discretion of the treating investigator, it is believed that it is safe to treat all sites of disease using SABR.\n6. All men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of standard of care SABR and for a period of time of 6 months thereafter as per standard guidelines. Should a patient's partner become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n7. Ability to understand and the willingness to sign a written informed consent.\n8. Planned for standard systemic therapy for metastatic prostate cancer to include androgen deprivation therapy (ADT). Upfront Docetaxel should not be planned (See section 4.1.2).\n\nExclusion Criteria:\n\n1. Prior radiotherapy to any metastases currently targeted for therapy or overlapping regions.\n2. Patient with metastatic lesions involving the gastrointestinal tract, specifically, invading esophagus, stomach, or intestines will be excluded. Patients with ultra-central metastatic lesions defined as 1 cm from the trachea and main bronchi will be excluded.\n3. Serious medical co-morbidities precluding safe delivering of radiotherapy to poly-metastatic sites. This includes interstitial lung disease for patients undergoing SABR to thoracic sites and ulcerative colitis or Crohn's disease requiring systemic immunosuppressive therapy for patients undergoing SABR to GI sites.\n4. Subjects may not be receiving any other PSMA-directed investigational agents for the treatment of the cancer under study.\n5. History of allergic reactions to PMSA-11 68Ga imaging agent.\n6. Uncontrolled intercurrent illness or psychiatric illness\u002Fsocial situations that, in the opinion of the investigator, would limit compliance with study requirements.","MALE",{"count":449,"type":23},30,[451],"EARLY_PHASE1","The purpose of this study is to characterize the reduction in PSMA-avid tumor volume and metastasis-directed radiotherapy treatment intensity facilitated by PET PSMA-response adapted SABR for poly-metastatic castration sensitive prostate cancer.",[454,455,456,457],"Prostate Cancer","Castration Sensitive Prostate Cancer","Metastatic Prostate Cancer","Adaptive Radiotherapy",[459,460,461,462,463,464,465],"prostate cancer","castration sensitive","stereotactic ablative radiotherapy","stereotactic body radiotherapy","metastatic prostate cancer","metastasis","adaptive radiotherapy","2026-07-21",{"date":434,"type":38},{"date":469,"type":23},"2026-07-15",{"date":471,"type":23},"2029-06-15",{"name":44,"class":45},{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":480,"enrollmentInfo":481,"targetDuration":4,"studyType":24,"phases":483,"briefSummary":484,"conditions":485,"keywords":488,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":499,"locationsCount":95},"100435966","motor-network-physiology-100435966","NCT04957095","Motor Network Physiology","Motor Network Physiology Characterization During Deep Brain Stimulation Surgery","Inclusion Criteria:\n\n* Diagnosis of Parkinson's disease who have been recommended to undergo deep brain stimulation for management of their movement disorder\n* Preoperative MRI without evidence of cortical or subdural adhesions or vascular abnormalities\n* Willingness and ability to cooperate during conscious operative procedure for up to 40 minutes\n\nExclusion Criteria:\n\n* Patients with recent use (within one week) of anticoagulant or antiplatelet agents\n* Neurocognitive testing indicating amnestic cognitive deficits","89 Years",{"count":482,"type":23},120,[26],"The brain networks controlling movement are complex, involving multiple areas of the brain. Some neurological disorders, like Parkinson's disease (PD) and essential tremor (ET), cause abnormalities in these brain networks. Deep brain stimulation is a treatment that is used to treat these types of neurological diseases and is thought to help patients by modulating brain networks responsible for movement. Levodopa medication is also used to modulate this brain networks in patients with PD. The overall objective is to develop a unified theory of basal ganglia thalamocortical (BGTC) circuit dynamics that accounts for disease symptomatology, movement, and their inter-relationship. The underlying hypothesis, is that the rigidity and bradykinesia of PD are fundamentally related to excessive functional coupling across nodes in the BGTC motor circuit impeding effective information flow. In this research, the investigator will take advantage of the unique opportunity provided by awake deep brain stimulation surgery to learn more about how the brain functions in a diseased state and how deep brain stimulation changes these networks to make movement more normal. The investigator will simultaneously assess cortical and subcortical electrophysiology in relation to clinical symptoms and behavioral measures and in response to deep brain stimulation, cortical stimulation, and pharmacologic therapy in patients undergoing Deep Brain Stimulation (DBS) implantation surgery.",[486,487],"Parkinson Disease","Essential Tremor",[489,490,491,492,493],"deep brain stimulation","levodopa medication","motor cortex","basal ganglia","thalamus","2026-07-20",{"date":432,"type":38},{"date":497,"type":38},"2022-02-18",{"date":133,"type":23},{"name":44,"class":45},{"id":501,"slug":502,"hasResults":12,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":4,"eligibilityCriteria":506,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":507,"enrollmentInfo":508,"targetDuration":4,"studyType":24,"phases":509,"briefSummary":510,"conditions":511,"keywords":520,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":530,"completionDateStruct":531,"leadSponsor":533,"locationsCount":95},"100648608","early-phase-1-human-cognition-during-surgery-stimulation-based-and-cholinergic-modulation-100648608","NCT07721272","Human Cognition During Surgery: Stimulation-based and Cholinergic Modulation","Studying Human Cognition During Deep Brain Stimulation Surgery Using High-Density Neural Probes and Pharmacological Interventions","Study Population\n\nInclusion Criteria for Essential Tremor Patients:\n\n* Diagnosis of Essential Tremor\n* Recommended to undergo deep brain stimulation implantation surgery for surgical management of medication-resistant tremor based on clinical indications\n\nExclusion Criteria for Essential Tremor Patients:\n\n* Patients with recent use (within one week) of anticoagulant or antiplatelet agent\n* Contraindication to use of cholinergic modulation\n\nInclusion Criteria for Epilepsy Patients\n\n* Diagnosis of intractable epilepsy\n* Undergoing neuromodulation procedure that utilizes insertion of electrodes into subcortical structures, including the thalamus or hippocampus\n* Undergoing neuromodulation procedure that utilizes frame-based insertion of electrodes into the thalamus (ANT or CM)\n\nExclusion Criteria for Epilepsy Patients:\n\n* Patients with recent use (within one week) of anticoagulant or antiplatelet agent\n* Contraindication to use of cholinergic modulation\n\nContraindication for cholinergic modulation in both patient sets will be assessed by members of the treatment team (e.g. epileptologist), as well as a neuroanesthesiologist. Multiple medications and conditions are singular disqualifiers; however some medications are eliminated only in combination following neuroanesthesiologist evaluation. Patients at risk of reaction to the treatment arm based on concurrent or recent medications or other health conditions will be excluded from participation.\n\nInclusion Criteria for Study Participation\n\n* Is patient between 18-70?\n* In general good health, aside from history of epilepsy or essential tremor, as ascertained by medical history, physical exam, clinical labs, and ECG?\n* Candidate for surgery as determined independently by the patient's treating physician\u002Fclinical team as part of the patient's routine medical care?\n* Able to read, understand, and provide written, dated informed consent, and participate in cognitive tasks?\n\nExclusion Criteria for Study Participation\n\n* Female that is pregnant, breastfeeding, or has a positive pregnancy test?\n* Under 18, over 70, or currently a prisoner on medical release?\n* Hepatic impairment (moderate or severe)?\n* Renal impairment (moderate or severe)?\n* Untreated narrow angle glaucoma?\n* Bladder obstruction, prostatic hyperplasia (BPH), diabetic cystopathy, pre-existing urinary retention?\n* History of hypersensitivity to COBENFY or trospium chloride?\n* Biliary disease, including symptomatic gallstones, gallbladder disorders, pancreatitis?\n* Fluoxetine, paroxetine, bupropion, terbinafine?\n* Buspirone or eletriptan?\n* Digoxin, colchicine, apixaban?\n* Diphenhydramine, beztropine, oxybutynin?\n* Benztropine, trihexyphenidyl, tolterodine, solifenacin, darifenacin, fesoterodine, hyoscyamine, dicyclomine, scopolamine?","70 Years",{"count":449,"type":23},[451],"This is a research study to determine how COBENFY KarXT (FDA approved), a drug which has been approved for treatment of certain disorders, affects brain activity and cognitive tasks which may be regulated by the cholinergic system.\n\nThis study aims to answer: 1) how cholinergic circuitries act during task performance in humans, and 2) develop a better understanding of how cognitive control interacts with learning, memory and decision making in the setting of cholinergic manipulation.\n\nParticipants will complete a single treatment arm, regardless of which surgical procedure they are to receive. An anesthesiologist or other clinical staff will administer either the drug or the saline at a critical point which addresses the research questions, prior to patient surgery. This will be either with the drug, or the placebo pill. Half of the participants will be randomized to receive the drug, and the other half of these the placebo. Participants will be unaware whether the actual drug has been received.\n\nEssential tremor patients who participate will complete a cognitive task during an awake surgery. Epilepsy patients who participate will have a resting state recording during the procedure from the deep cortical layers of the brain. A probe will be used during the surgery to measure the effects of this drug and other procedures of the study on the cholinergic system. This probe is the clinical probe known as the AlphaOmega, which is FDA approved for standard of care procedures.\n\nResearchers will compare the brain activity between treatment arms to determine what brain activity changes based on the cholinergic manipulation.",[512,487,513,514,515,516,517,518,519],"Epilepsy","Seizures","Memory Consolidation","Memory Disorders","Memory Replay","Memory Encoding","Cognitive Control","Motor Abilities",[521,522,523,524,525,526,527],"interoperative","oscillatory changes","neuronal spiking","time cell","place cell","cholinergic agonist","cholinergic modulation","2026-07-17",{"date":434,"type":38},{"date":209,"type":23},{"date":532,"type":23},"2030-09",{"name":44,"class":45},{"id":535,"slug":536,"hasResults":12,"nctId":537,"briefTitle":538,"officialTitle":539,"acronym":4,"eligibilityCriteria":540,"healthyVolunteers":12,"sex":18,"minAge":541,"maxAge":4,"enrollmentInfo":542,"targetDuration":4,"studyType":24,"phases":544,"briefSummary":545,"conditions":546,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":548,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":95},"100501983","phase-2-long-term-efficacy-and-safety-of-orlistat-for-type-1-hyperlipoproteinemia-100501983","NCT05816343","Long Term Efficacy and Safety of Orlistat for Type 1 Hyperlipoproteinemia","Long Term Efficacy and Safety of Orlistat for Type 1 Hyperlipoproteinemia: a Randomized, Double-blind, Placebo-controlled Trial","Inclusion criteria:\n\n* Age ≥ 8 years\n* Type I hyperlipoproteinemia confirmed by bi-allelic disease-causing variants in any one of the T1HLP genes (LPL, APOC2, APOA5, LMF1, GPIHBP1, or GCKR).\n* Subjects with digenic inheritance with heterozygous disease-causing variants in two different T1HLP genes.\n* Subjects who have a fasting TG greater than or equal to 750 mg\u002FdL at the end of run-in period of 8 weeks will be eligible for randomization.\n* Subjects who do not have confirmed genetic mutation for Type 1 hyperlipoproteinemia but have a fasting TG greater than or equal to 750 mg\u002FdL at the end of run-in period of 8 weeks will be eligible for randomization.\n* Well controlled diabetes mellitus with hemoglobin A1c \\\u003C 8%\n* Off orlistat for a period of 2 months\n* Patients on Olezarsen and Plozasiran (APOC3 antisense oligonucleotide) can enroll if on the drug for more than 3 months\n* Following methods of contraception for males and females of childbearing age will be employed Males: Being in this research may damage your sperm, which could cause harm to a child that you may father while on this study. If you take part in this study and are sexually active, you must agree to use a medically-acceptable form of birth control. Medically-acceptable forms of birth control include: (1) surgical sterilization (vasectomy), or (2) a condom used with a spermicide (a substance that kills sperm).\n\nFemales: If you are part of this study while pregnant or breast-feeding an infant, it is possible that you may expose the unborn child or infant to risks. For that reason, pregnant and breast-feeding females cannot participate in the study. If you can become pregnant, a blood or urine pregnancy test will be done, and it must be negative before you participate in this study. If you take part in this study and you are sexually active, you and any person that you have sex with must use medically-acceptable birth control (contraceptives) during the study. Medically-acceptable birth control (contraceptives) includes: (1) surgical sterilization (such as hysterectomy or \"tubes tied\"), (2) approved hormonal contraceptives (such as birth control pills, patch or ring; Depo-Provera, Implanon), (3) barrier methods (such as condom or diaphragm) used with a spermicide (a substance that kills sperm), or (4) an intrauterine device (IUD). If you do become pregnant during this study, you must tell the researchers immediately.\n\nExclusion Criteria:\n\n* Secondary hypertriglyceridemia due to diabetes, renal disease, alcoholism and drug therapy such as estrogens and estrogen analogues, steroids, HIV-1 protease inhibitors, retinoic acid derivatives, interferons, or lasparaginase.\n* On lomitapide or participating in clinical trial of volanesorsen.\n* On cyclosporine\n* Having serum TSH outside of the normal range if on levothyroxine supplementation.\n* Use of levothyroxine to suppress TSH in individuals with thyroid cancer.\n* Pregnant or lactating women\n* Significant liver disease (elevated transaminases \\> 2 times upper limit of normal)\n* Alcohol abuse (\\> 7 drinks or 84 g per week for women and \\> 14 drinks or 168 g per week for men)\n* Severe anemia (hematocrit \\\u003C 24%)\n* Illicit drug use (cocaine, marijuana, LSD, etc.)\n* Major surgery in the past three months\n* Congestive heart failure\n* Serum creatinine greater than 2.5 mg\u002FdL\n* Cancer within the past five years\n* Gastrointestinal surgery in the past\n* Current therapy with anti-coagulants, digoxin and anti-arrhythmics\n* Chronic malabsorption syndromes\n* Cholestasis\n* Acute illnesses such as acute pancreatitis in the last 8 weeks\n* Previous history of renal calcium oxalate stones","8 Years",{"count":543,"type":23},28,[58],"Type I hyperlipoproteinemia (T1HLP, also known as familial chylomicronemia syndrome or FCS) is a rare diseasewhere the blood triglycerides (fats) are very high. It is caused by lack of certain enzymes and proteins in the bodythat are important in disposing circulating fats from blood. Treatment of T1HLP patients who have very high levels of blood fats (≥ 1,000 mg\u002FdL) is challenging as conventional triglyceride-lowering medications, such as fibrates and fishoil, are ineffective.\n\nThe purpose of this trial is to study the long-term efficacy and safety of orlistat for reducing blood triglyceride levels in patients with T1HLP.",[547],"Type 1 Hyperlipoprotenemia",{"date":466,"type":38},{"date":550,"type":38},"2024-01-26",{"date":552,"type":23},"2029-05-30",{"name":44,"class":45},{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":4,"eligibilityCriteria":560,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":561,"targetDuration":4,"studyType":24,"phases":562,"briefSummary":563,"conditions":564,"keywords":566,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":95},"100648311","impact-of-foot-orthoses-on-gait-in-individuals-with-ataxia-100648311","NCT07720700","Impact of Foot Orthoses on Gait in Individuals With Ataxia","Prospective Evaluation of Functional Performance in Patients With Lower Limb Orthoses","Inclusion Criteria:\n\n* Cerebellar ataxia diagnosed by a physician\n* Ambulatory for 16 feet (Zeno mat) with assistance and without assistive device(s)\n* 18 years or older\n\nExclusion Criteria:\n\n* Gait velocity \\>\u002F= 100 cm\u002Fsec without an assistive device\n* Medically diagnosed orthopedic conditions or injuries that impact ambulation\n* Unhealed wounds on the feet",{"count":392,"type":23},[26],"This study is the first to assess the impact of lower extremity orthoses on gait and balance in individuals with CA. By investigating how orthoses influence mobility and stability, this research will provide critical data to inform clinical guidelines, improve patient care, and support evidence-based orthotic prescriptions for individuals with CA.",[565],"Ataxia",[565,567,568],"Orthoses","Gait","2026-07-16",{"date":432,"type":38},{"date":572,"type":38},"2025-11-21",{"date":574,"type":23},"2027-12",{"name":44,"class":45},{"id":577,"slug":578,"hasResults":12,"nctId":579,"briefTitle":580,"officialTitle":580,"acronym":581,"eligibilityCriteria":582,"healthyVolunteers":12,"sex":18,"minAge":583,"maxAge":4,"enrollmentInfo":584,"targetDuration":4,"studyType":24,"phases":586,"briefSummary":587,"conditions":588,"keywords":594,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":600,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":605,"locationsCount":95},"100473568","phase-2-pathways-relating-amnestic-mci-to-a-mild-traumatic-brain-injury-history-100473568","NCT05446584","Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History","PATH","Inclusion Criteria:\n\n1. Active diagnosis of amnestic mild cognitive impairment\n2. Presence of an mTBI history for the mTBI+ group; absence of an mTBI history for a control sample\n3. Female and male subjects\n4. All races\u002Fethnicities\n5. Age 55 years and older\n6. Fluent in English\n\nExclusion Criteria:\n\n1. Mild traumatic brain injury within past year\n2. Lifetime history of moderate or severe brain injury\n3. Lifetime major neurologic syndromes (e.g., stroke, epilepsy, brain tumor)\n4. Lifetime major cardiovascular conditions (e.g., heart attack, heart failure)\n5. Current substance use disorder\n6. Current major psychiatric disorders (e.g., major depressive disorder, bipolar disorder)\n7. Current vision or hearing impairment that interferes with testing\n8. Any electronic and or metallic implants in the skull or brain\n9. Current medication use known to alter HD-tDCS reactivity","55 Years",{"count":585,"type":23},75,[58],"This study will probe if the biological changes in amnestic mild cognitive impairment (aMCI) are related to a history of mild traumatic brain injury (mTBI) using high definition transcranial direct current stimulation (HD-tDCS) and blood-derived biomarker tools. Participants who Do as well as those who Do Not have a history of mTBI will be enrolled in the study.",[589,590,591,592,593],"Mild Cognitive Impairment","Amnestic Mild Cognitive Disorder","Amnestic Mild Cognitive Impairment","Mild Traumatic Brain Injury","Concussion, Brain",[595,596,597,598,599],"MCI","TBI","memory","biomarker","Alzheimer",{"date":494,"type":38},{"date":602,"type":38},"2023-04-20",{"date":604,"type":23},"2027-05-31",{"name":44,"class":45},{"id":607,"slug":608,"hasResults":12,"nctId":609,"briefTitle":610,"officialTitle":611,"acronym":4,"eligibilityCriteria":612,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":613,"targetDuration":4,"studyType":336,"phases":4,"briefSummary":615,"conditions":616,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":618,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":623,"locationsCount":95},"100470145","cancer-clinical-trials-financial-reimbursement-program-100470145","NCT05402033","Cancer Clinical Trials Financial Reimbursement Program","Enhancement of Access to and Diversity in Cancer Clinical Trials Through a Financial Reimbursement and Outreach Program","Inclusion Criteria:\n\n* Be enrolled in a therapeutic cancer clinical trial\n* Speak English or Spanish\n\nExclusion Criteria:\n\n* Not enrolled in a clinical trial\n* Does not speak English or Spanish",{"count":614,"type":23},1200,"To implement a Financial Reimbursement and Outreach Program at clinical sites within the Harold C. Simmons Comprehensive Cancer Center; and evaluate the impact of the program on clinical trial enrollment and demographics, as well as facilitators of and barriers to program participation.",[617],"Cancer Clinical Trials",{"date":494,"type":38},{"date":620,"type":38},"2022-07-12",{"date":622,"type":23},"2030-06-01",{"name":44,"class":45},{"id":625,"slug":626,"hasResults":12,"nctId":627,"briefTitle":628,"officialTitle":629,"acronym":4,"eligibilityCriteria":630,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":358,"enrollmentInfo":631,"targetDuration":4,"studyType":24,"phases":633,"briefSummary":634,"conditions":635,"keywords":637,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":639,"startDateStruct":640,"completionDateStruct":641,"leadSponsor":643,"locationsCount":95},"100637026","phase-1-a-safety-and-tolerability-study-of-cc--97540-bms-086353-in-anti-aquaporin-4-antibody-positive-neuromyelitis-optica-patients-100637026","NCT07573332","A Safety and Tolerability Study of CC- 97540 (BMS-086353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients","A Multicenter, Phase 1, Safety and Tolerability Study of CC-97540 (BMS- 986353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients","Inclusion Criteria:\n\n1. Signed written informed consent\n\n   a. Participants must have signed and dated an Institutional Review Board (IRB)\u002FIndependent Ethics Committee (IEC)-approved written ICF in accordance with regulatory, local, and institutional guidelines. This must be obtained before the performance of any protocol-related procedures that are not part of normal patient care.\n2. Age 18 to 60 inclusive\n3. Diagnosis of anti-AQP4 antibody positive NMOSD by 2015 Wingerchuk IPND criteria\n4. No relapses within last 12 months\n5. Stable ravulizumab or satralizumab dosing for at least 6 months\n6. Up to date on meningococcal vaccines and enrolled in any required REMS program\n7. EDSS score of 6.5 or less\n8. At least one eye best visual acuity 20\u002F200 or better\n9. Peripheral B cell count by flow cytometry of \\>5%\n10. Positive anti-AQP4 antibody test on cell based assay at screening\n11. Patient has adequate vascular access for leukapheresis\n12. ALT and AST \\\u003C1.5x upper limit of normal\n\nExclusion Criteria:\n\n1. History of active meningococcal disease\n2. Presence of active, clinically significant concomitant CNS pathology, other than NMOSD, that may confound the ability to interpret study results, including but not limited to, seizure disorder, traumatic brain injuries, delirium, Parkinson's disease, psychosis, Neuro-Behcet's disease, Guillain-Barré syndrome, metabolic or infectious cause of myelopathy, genetically-inherited progressive CNS disorder, ischemic cerebrovascular disorders, including, but not limited to, transient ischemic attack, subarachnoid hemorrhage, cerebral thrombosis, cerebral embolism, or cerebral hemorrhage; CNS sarcoidosis; history of anti- myelin oligodendrocyte glycoprotein antibody-associated disorder or a diagnosis of progressive multifocal leukoencephalopathy (PML) or history of PML; or of infectious or autoimmune encephalitis or meningitis under prior DMT.\n3. Any significant medical condition, laboratory test abnormality or psychiatric Active infection requiring treatment\n4. Hypersensitivity or allergy to fludarabine, cyclophosphamide, excipients of CC- 97540, ravulizumab, tocilizumab or satralizumab.\n5. condition that would pose a risk the participant's safety from participating in the study.\n6. Active autoimmune condition other than NMOSD that requires immunotherapy\n7. History of any one of the following cardiovascular conditions within the 6 months prior to screening: Class III or IV heart failure as defined by the New York Heart Association, myocardial infarction, unstable angina, angioplasty or stenting, or other clinically significant cardiac disease.\n8. Uncontrolled medical, psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol, as judged by the investigator; or unwillingness or inability to follow the procedures required in the protocol.\n9. Prior history of malignancies or lymphoproliferative disease, unless the participant has been free of the disease for ≥ 2 years. The following are allowed:\n\n   1. Basal or squamous cell carcinoma of the skin.\n   2. Carcinoma in situ of the cervix or breast.\n   3. Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis clinical staging system) or prostate cancer that is curative.\n   4. Other completely resected Stage I solid tumor with low risk for recurrence.\n10. Active syphilis, any human immunodeficiency virus, human lymphocytic T-cell virus type 1 and\u002For type 2, or active or latent tuberculosis infection.\n11. Known chronic, active hepatitis B or C virus (HBV\u002FHCV) infection or untreated prior HCV infection (positive HCV IgG result). Participants who had HCV but have received an antiviral treatment and show no detectable HCV viral RNA for 6 months are eligible. Participants with no active hepatitis B infection (eg, hepatitis B surface antigen \\[HBsAg\\] negative, anti-hepatitis B core antibody \\[HBcAb\\]positive) who are under adequate prophylaxis against HBV re-activation may be eligible; such participants must be screened using real-time polymerase chain reaction (PCR) measurement of HBV DNA levels or viral load; those who are PCR positive will be excluded. Participants who have received HBV vaccine and are hepatitis B surface antibody (HBsAb) positive, HBcAb negative, and HBsAg negative are eligible for study entry.\n12. Uncontrolled or active systemic fungal, bacterial, viral, or other infection despite appropriate anti-infective treatment at the time of leukapheresis, or within 72hours before LD chemotherapy, or 5 days before CC-97540 (BMS-986353) administration.\n13. Use of any live vaccines against infectious disease within 6 weeks prior to the start of lymphodepleting therapy, during CC-97540 (BMS-986353) infusion, and until immune recovery.\n14. Previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 10 days for mild or asymptomatic infections or 20 days for severe\u002Fcritical illness prior to leukapheresis or initiation of LD chemotherapy. Acute symptoms must have resolved and based on investigator assessment there are no sequelae that would place the participant at a higher risk of receiving study treatment.\n15. Any condition that confounds the ability to interpret data from the study.\n16. Participants who are not up to date on all recommended vaccinations per local\u002Fnational Health Authority (eg, Centers for Disease Control and Prevention) or institutional guidelines for immunocompromised individuals. For vaccines requiring more than one dose, the full series (eg, both doses of a 2-dose series) should be completed prior to leukapheresis or initiation of LD chemotherapy when feasible and when a delay in leukapheresis or initiation of LD chemotherapy would not put the study participant at risk.\n17. An answer of \"yes\" to items 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS) at Screening (for the past 6-months interval).\n18. Pregnancy or nursing women\n19. Prior CAR T therapy\n20. Stem cell transplantation within one year of screening\n21. Positive Quantiferon test\n22. Prisoners or participants who are involuntarily incarcerated.\n23. Contraindications against MRI imaging, including non-MRI compatible metal implants, cardiac pacemakers, cochlear implants, ventricular shunt systems; metal particles in the body that pose a risk to the participant, including large tattoos in regions affected by cranial\u002Fneck MRI scanning, and severe claustrophobia. Contraindications against gadolinium-based contrast agents, including known hypersensitivity to gadolinium-based contrast agents.",{"count":632,"type":23},5,[57],"The goal of this clinical trial is to find out if the investigational medicine BMS-986353 is safe and well tolerated in adults with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a long-term autoimmune condition that affects the optic nerves and spinal cord and can lead to relapses. Most people with NMOSD have antibodies against AQP4, which are linked to future disease activity.\n\nThe main questions this study aims to answer are:\n\n\"-\" Is CC-97540 (BMS-986353) safe and well tolerated, based on how many participants experience serious side effects that limit dosing (called dose-limiting toxicities)?\n\n\"-\" Does CC-97540 (BMS-986353) show early signs of benefit, based on how many participants no longer have detectable AQP4 antibodies in their blood (called sero-reversion)?\n\nParticipants are adults aged 18 to 60 years with AQP4 antibody-positive NMOSD who are currently clinically stable on ravulizumab or satralizumab. Approved NMOSD treatments reduce relapses by changing how the immune system works, but they do not remove the cells that make AQP4 antibodies. This study is designed to see whether BMS-986353 can target these cells without the need for long-term immune suppression.\n\nParticipants will:\n\n\"-\" Receive CC-97540 (BMS-986353) as part of the study \"-\" Continue their current NMOSD therapy \"-\" Attend study visits for safety checks, exams, and lab tests",[636],"AQP4+ NMOSD",[638,636],"anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder",{"date":528,"type":38},{"date":276,"type":23},{"date":642,"type":23},"2031-08-01",{"name":44,"class":45},{"id":645,"slug":646,"hasResults":12,"nctId":647,"briefTitle":648,"officialTitle":649,"acronym":4,"eligibilityCriteria":650,"healthyVolunteers":17,"sex":18,"minAge":651,"maxAge":4,"enrollmentInfo":652,"targetDuration":654,"studyType":336,"phases":4,"briefSummary":655,"conditions":656,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":658,"startDateStruct":659,"completionDateStruct":661,"leadSponsor":663,"locationsCount":95},"100538535","phenotyping-of-postural-orthostatic-tachycardia-syndrome-pots-100538535","NCT06292104","Phenotyping of Postural Orthostatic Tachycardia Syndrome (POTS)","Multimodality Deep Phenotyping of Postural Orthostatic Tachycardia Syndrome (POTS), Aim 1","Inclusion Criteria:\n\nPOTS Patients\n\n* Age ≥ 14 years, able to provide informed consent (assent with parental consent for age \\\u003C 18) and comply with procedures\n* Meets consensus criteria for POTS: (1) sustained increase in heart rate ≥ 30 bpm above supine baseline within 10 min of quiet standing or upright tilt (≥ 40 bpm in individuals 12 to 19 years of age) OR sustained upright HR (heart rate) \\>120 bpm, (2) absence of orthostatic hypotension, (3) symptoms with standing that improve with sitting or lying down, (4) resting supine heart rate \\\u003C 100 bpm, (5) orthostatic symptoms present for at least 6 months\n* Stable oral medication regimen for at least 14 days\n\nNon-POTS Control Patients\n\n* Healthy women, age 18 - 30 years, able to provide informed consent and comply with study procedures\n* Does NOT meet consensus criteria for postural tachycardia syndrome\n* No symptoms of orthostatic intolerance or dysautonomia. No history of other major medical disorder\n* Resting supine heart rate \\\u003C 100 bpm\n\nExclusion Criteria:\n\nNone of the following exclusion criteria:\n\n* Use of amphetamine-type stimulants, diuretics, selective norepinephrine reuptake inhibitor, anticholinergic medications (including tricyclic antidepressant medications), fludrocortisone, desmopressin in past 14 days\n* Use of other autonomic drugs (adrenergic agents, pyridostigmine, droxidopa, triptans, ivabradine) in past 48 hours\n* Currently receiving IVIG (Intravenous immunoglobulin), subcutaneous IgG (Immunoglobulin G), or any investigational medication (in past year)\n* Infusion of iv fluids in past 7 days\n* History or evidence of another condition explaining symptoms or orthostatic tachycardia (e.g. structural heart disease, CSF (Cerebrospinal fluid) hypovolemia, or severe traumatic brain injury)","14 Years",{"count":653,"type":23},350,"1 Year","This is an observational study to deeply phenotype the disorder of POTS using multiple testing modalities.",[657],"Postural Orthostatic Tachycardia Syndrome",{"date":528,"type":38},{"date":660,"type":38},"2024-03-05",{"date":662,"type":23},"2029-01",{"name":44,"class":45},{"id":665,"slug":666,"hasResults":12,"nctId":667,"briefTitle":668,"officialTitle":669,"acronym":4,"eligibilityCriteria":670,"healthyVolunteers":17,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":671,"targetDuration":4,"studyType":336,"phases":4,"briefSummary":673,"conditions":674,"keywords":676,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":678,"startDateStruct":679,"completionDateStruct":681,"leadSponsor":682,"locationsCount":95},"100132372","collecting-tissue-samples-from-patients-with-cancer-undergoing-radiation-therapy-and-healthy-participants-100132372","NCT00992303","Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants","Tissue Procurement and Outcome Collection for Radiotherapy Treated Patients and Healthy Participants","DISEASE CHARACTERISTICS:\n\n* Pathologically-proven diagnosis of malignancy\n* Planning treatment with radiation therapy\n\nPATIENT CHARACTERISTICS:\n\n* Able to perform follow-up visits\n* Is a patient of the University of Texas Southwestern Medical Center physicians\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* Participation in other clinical trials is allowed\n* Other prior or concurrent therapy for cancer, such as surgery and\u002For chemotherapy, is allowed.\n\nCriteria for eligibility:\n\n* Able to provide written informed consent\n* Age greater than 18 years old\n* Males and Females are eligible\n* Any ethnicity is eligible\n\nCriteria for ineligibility:\n\n-Patients not available for follow-up\u002Ffuture contact",{"count":672,"type":23},10000,"RATIONALE: Collecting and storing samples of tissue from patients with cancer to test in the laboratory may help the study of cancer in the future.\n\nPURPOSE: This research study is collecting tissue samples from patients with cancer undergoing radiation therapy. Healthy participants will also be allowed on the trial so their samples can be used in comparison to patients with malignancy",[675],"Unspecified Adult Solid Tumor, Protocol Specific",[677],"unspecified adult solid tumor, protocol specific",{"date":528,"type":38},{"date":680,"type":4},"2009-09",{"date":42,"type":23},{"name":44,"class":45},""]